Latest Regulatory Milestones News

Meteoric Resources has reported strong pilot plant performance and advanced feasibility work at its Caldeira rare earths project, alongside a $50 million non-binding financing letter from Export Finance Australia and robust Brazilian government backing.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Talga Group reported record anode production at its EVA plant and significant progress on its 5,000tpa Vittangi anode plant FEED study, alongside strategic partnerships and exploration breakthroughs.

European Metals Holdings has secured critical regulatory milestones for its Cinovec Lithium Project, submitting the full Environmental Impact Assessment and obtaining Regional Rezoning approval. The company also raised A$3.46 million to support ongoing development.

Cleo Diagnostics (ASX:COV) has hit a major milestone by completing sample collection for its pivotal U.S. ovarian cancer trial, while progressing manufacturing and analytical validation steps toward FDA 510(k) submission.

Sky Metals has bolstered its cash reserves with a $20.5 million raise, backing a major drilling push at Tallebung and expanding exploration at Doradilla, positioning both projects for significant resource growth and development progress.

Invictus Energy is gearing up for a pivotal drilling campaign in Zimbabwe's Cabora Bassa Basin, targeting a multi-Tcf gas and condensate resource that could reshape Southern Africa's energy landscape.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.